Sensitive analysis of 1α,25-dihydroxyvitamin D3 in biological fluids by liquid chromatography-tandem mass spectrometry

被引:27
作者
Kissmeyer, AM [1 ]
Sonne, K [1 ]
机构
[1] Leo Pharmaceut Prod, Dept Pharmacokinet & Metab, DK-2750 Ballerup, Denmark
关键词
validation; stability studies; vitamins; seocalcitol; calcitriol;
D O I
10.1016/S0021-9673(01)00985-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A liquid chromatographic-tandem mass spectrometric assay using 5% bovine serum albumin as the calibration matrix has been developed for the quantitative analysis of 1 alpha ,25-dihydroxyvitamin D-3 [1 alpha ,25(OH)(2)D-3] in biological fluids. The analyte was extracted from the matrix after protein precipitation using an automated solid-phase extraction procedure involving both a reversed-phase and normal-phase procedure on a single C-18 cartridge. The analytical chromatography was performed using a Symmetry C-8 50x2.1 mm, 3.5 mum column. The mobile phase was a linear gradient from 75 to 99% methanol with a constant concentration of 2 mM ammonium acetate, 1 alpha ,25(OH)(2)D-3 and the internal standard [H-2(6)]1 alpha ,25(OH)(2)D-3 were detected by using MS-MS. The ion source was operated in the positive electrospray ionisation mode. The assay is specific, sensitive, and has a capacity of more than 100 samples per day, with a limit of quantitation of 20 pg ml(-1) for a 1.0-ml sample aliquot. The assay has been used for the analysis of 1 alpha ,25(OH)(2)D-3 in serum from rats and pigs simultaneously with the analysis of the vitamin D analog seocalcitol. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 42 条
[1]   Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism [J].
Akiba, T ;
Marumo, F ;
Owada, A ;
Kurihara, S ;
Inoue, A ;
Chida, Y ;
Ando, R ;
Shinoda, T ;
Ishida, Y ;
Ohashi, Y .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (02) :238-246
[2]   A highly sensitive method for large-scale measurements of 1,25-dihydroxyvitamin D [J].
Arbour, NC ;
Ross, TK ;
Zierold, C ;
Prahl, JM ;
DeLuca, HF .
ANALYTICAL BIOCHEMISTRY, 1998, 255 (01) :148-154
[3]   IMPORTANCE OF CIRCULATING 1,25-DIHYDROXYVITAMIN-D IN THE PATHOGENESIS OF HYPERCALCIURIA AND RENAL-STONE FORMATION IN PRIMARY HYPERPARATHYROIDISM [J].
BROADUS, AE ;
HORST, RL ;
LANG, R ;
LITTLEDIKE, ET ;
RASMUSSEN, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 302 (08) :421-426
[4]  
DALHOFF K, 1998, HEPATOLOGY, V28, P2
[5]  
DELUCA HF, 1976, CALC TISS RES, V21, P128
[6]   THE EFFECT OF 22-OXACALCITRIOL ON SERUM CALCITRIOL [J].
DUSSO, AS ;
NEGREA, L ;
FINCH, J ;
KAMIMURA, S ;
LOPEZHILKER, S ;
MORI, T ;
NISHII, Y ;
BROWN, A ;
SLATOPOLSKY, E .
ENDOCRINOLOGY, 1992, 130 (06) :3129-3134
[7]   Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer [J].
Fraser, WD ;
Durham, BH ;
Berry, JL ;
Mawer, EB .
ANNALS OF CLINICAL BIOCHEMISTRY, 1997, 34 :632-637
[8]   Intermittent oral 1α-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients [J].
Frazao, JM ;
Chesney, RW ;
Coburn, JW .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 :68-72
[9]  
Glade CP, 1998, CLIN EXP DERMATOL, V23, P14
[10]   Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis [J].
Goldenberg, MM .
CLINICAL THERAPEUTICS, 1999, 21 (03) :432-441